- Home
- PGEN vs NFJ Comparison
PGEN vs NFJ Comparison
Compare PGEN & NFJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PGEN | NFJ |
|---|---|---|
| Founded | 1998 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | PGEN | NFJ |
|---|---|---|
| Price | $4.12 | $14.23 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $8.33 | N/A |
| AVG Volume (30 Days) | ★ 2.8M | 181.6K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.01% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $230,981,000.00 | N/A |
| Revenue This Year | $1,115.92 | N/A |
| Revenue Next Year | $81.04 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.23 | $11.71 |
| 52 Week High | $5.47 | $14.29 |
Technical Indicators
Market Signals| Indicator | PGEN | NFJ |
|---|---|---|
| Relative Strength Index (RSI) | 54.94 | 70.66 |
| Support Level | $3.91 | $12.70 |
| Resistance Level | $4.31 | N/A |
| Average True Range (ATR) | 0.19 | 0.15 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 64.01 | 90.32 |
Price Performance
Historical ComparisonAbout PGEN Precigen Inc.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
About NFJ Virtus Dividend Interest & Premium Strategy Fund of Beneficial Interest
Virtus Dividend, Interest & Premium Strategy Fund is a Massachusetts-based business trust. The primary investment objective of the company is to seek current income and gains, with a secondary objective of long-term capital appreciation. It pursues its investment objectives by investing in a diversified portfolio of dividend-paying common stocks and income-producing convertible securities.